Sawai’s US Upsher-Smith business has reshaped its portfolio with a pair of deals that will see the firm add a “near-term” generic product opportunity to an existing partnership with Appco, as well as divesting two dormant abbreviated new drug applications in favor of a focus on near-term assets.
Announcing that it had “expanded its ongoing partnership with Appco Pharma with the addition of a near-term generic product opportunity to its portfolio,” Upsher-Smith said this formed part of a “company-wide effort to grow the company’s